Autolus Therapeutics (AUTL) Cash & Current Investments (2017 - 2026)

Autolus Therapeutics (AUTL) has 9 years of Cash & Current Investments data on file, last reported at $300.7 million in Q4 2025.

• Quarterly Cash & Current Investments fell 48.86% year-over-year to $300.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $300.7 million (down 48.86% YoY) and the FY2025 annual result came in at $300.7 million, down 48.86% from the prior year.
• Cash & Current Investments retreated to $300.7 million in Q4 2025, from $367.4 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $759.5 million in Q1 2024 to a low of $163.4 million in Q3 2022.
• A 5-year average of $373.6 million and a median of $309.3 million in 2021 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2021 — Cash & Current Investments jumped 39426.21% — and 2025, when it slumped 48.86%.
• Tracing AUTL's Cash & Current Investments over 5 years: stood at $310.7 million in 2021, then increased by 23.2% to $382.8 million in 2022, then sank by 37.21% to $240.3 million in 2023, then soared by 144.67% to $588.0 million in 2024, then tumbled by 48.86% to $300.7 million in 2025.
• The last three Cash & Current Investments figures came in at $300.7 million (Q4 2025), $367.4 million (Q3 2025), and $454.3 million (Q2 2025), per Business Quant data.